Search company, investor...


Founded Year



Acq - Pending | Acquired

Total Raised


About Aprogen

As of June 15, 2022, Aprogen merged with Aprogen Medicines. Aprogen is a Korean biopharmaceutical company that develops and manufactures biosimilars and biologics with its proprietary protein engineering technologies, including a patented bispecific antibody-engineering platform. Aprogen’s proprietary cell-engineering technology, combined with an advanced perfusion cell culture technology, ensures an extremely high yield of protein production in mammalian cell culture; multiple folds greater than that of the industry average. It was founded in 2000 and is based in Seongnam-Si, South Korea.

Headquarters Location

545, Dunchon-daero Jungwon-gu, Seongnam-si, Gyeonggi-do

Seongnam-Si, 13215,

South Korea

+82 31 625 4045

Missing: Aprogen's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Aprogen's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Aprogen

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Aprogen in 1 CB Insights research brief, most recently on May 28, 2020.

Expert Collections containing Aprogen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aprogen is included in 2 Expert Collections, including Unicorns- Billion Dollar Startups.


Unicorns- Billion Dollar Startups

1,201 items


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Aprogen Patents

Aprogen has filed 1 patent.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Proteins
  • Carbonic anhydrase inhibitors
patents chart

Application Date

Grant Date


Related Topics




Carbonic anhydrase inhibitors, Sulfonamides, Clusters of differentiation, Transcription factors, Proteins


Application Date


Grant Date



Related Topics

Carbonic anhydrase inhibitors, Sulfonamides, Clusters of differentiation, Transcription factors, Proteins



Latest Aprogen News

Aprogen Bidding for cGMP Production Facility in the U.S.

Nov 2, 2022

Aprogen Bidding for cGMP Production Facility in the U.S. Share Aprogen Bidding for cGMP Production Facility in the U.S. By Choi Moon-hee Aprogen’s plant in Osong Aprogen has joined a race to take over a current good manufacturing practice (cGMP) production facility in North Carolina of the United States. The move reflects its strategy to quickly advance into the U.S. market in response to U.S. President Joe Biden’s policy to favor U.S.-made biotech products. Aprogen announced on Nov. 1 that it has submitted a proposal to the lead manager of the tender, without disclosing the details of its offer. According to the company, the facility produces finished drugs approved by the U.S. Food and Drug Administration (FDA) for global pharmaceutical companies in Korea, Denmark, and Canada among others. It can make liquid and freeze-dried formulations. The 7,500-square-meter manufacturing facility was renovated with the latest equipment in 2015. Aprogen completed process validation and pilot production at this production facility to produce raw materials for biosimilars in the United States. As for the acquisition method, Aprogen is negotiating a plan to acquire new shares through a capital increase without using cash equivalents. POPULAR

Aprogen Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Aprogen Rank

Aprogen Frequently Asked Questions (FAQ)

  • When was Aprogen founded?

    Aprogen was founded in 2000.

  • Where is Aprogen's headquarters?

    Aprogen's headquarters is located at 545, Dunchon-daero, Seongnam-Si.

  • What is Aprogen's latest funding round?

    Aprogen's latest funding round is Acq - Pending.

  • How much did Aprogen raise?

    Aprogen raised a total of $62.12M.

  • Who are the investors of Aprogen?

    Investors of Aprogen include Aprogen Medicines, Lindeman Asia Investment and Nichi-Iko Pharmaceutical.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.